CPT/HCPCS:
|
A9699 | Radiopharmaceutical, therapeutic, not otherwise classified |
C9399 | Unclassified drugs or biologicals |
J0202 | Injection, alemtuzumab, 1 mg |
J0223 | Injection, givosiran, 0.5 mg |
J0256 | Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg |
J0257 | Injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg |
J0596 | Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units |
J0597 | Injection, c 1 esterase inhibitor (human), berinert, 10 units |
J0598 | Injection, c 1 esterase inhibitor (human), cinryze, 10 units |
J0896 | Injection, luspatercept aamt, 0.25 mg |
J1290 | Injection, ecallantide, 1 mg |
J1300 | Injection, eculizumab, 10 mg |
J1301 | Injection, edaravone, 1 mg |
J1303 | Injection, ravulizumab cwvz, 10 mg |
J1322 | Injection, elosulfase alfa, 1 mg |
J1458 | Injection, galsulfase, 1 mg |
J1459 | Injection, immune globulin (privigen), intravenous, non lyophilized (e.g., liquid), 500 mg |
J1460 | Injection, gamma globulin, intramuscular, 1 cc |
J1554 | Injection, immune globulin (asceniv), 500 mg |
J1555 | Injection, immune globulin (cuvitru), 100 mg |
J1556 | Injection, immune globulin (bivigam), 500 mg |
J1557 | Injection, immune globulin, (gammaplex), intravenous, non lyophilized (e.g., liquid), 500 mg |
J1558 | Injection, immune globulin (xembify), 100 mg |
J1559 | Injection, immune globulin (hizentra), 100 mg |
J1560 | Injection, gamma globulin, intramuscular, over 10 cc |
J1561 | Injection, immune globulin, (gamunex c/gammaked), non lyophilized (e.g., liquid), 500 mg |
J1562 | Injection, immune globulin (vivaglobin), 100 mg |
J1566 | Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg |
J1568 | Injection, immune globulin, (octagam), intravenous, non lyophilized (e.g., liquid), 500 mg |
J1569 | Injection, immune globulin, (gammagard liquid), non lyophilized, (e.g., liquid), 500 mg |
J1572 | Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non lyophilized (e.g., liquid), 500 mg |
J1575 | Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin |
J1599 | Injection, immune globulin, intravenous, non lyophilized (e.g., liquid), not otherwise specified, 500 mg |
J1602 | Injection, golimumab, 1 mg, for intravenous use |
J1632 | Injection, brexanolone, 1 mg |
J1743 | Injection, idursulfase, 1 mg |
J1744 | Injection, icatibant, 1 mg |
J1745 | Injection, infliximab, excludes biosimilar, 10 mg |
J1931 | Injection, laronidase, 0.1 mg |
J2182 | Injection, mepolizumab, 1 mg |
J2323 | Injection, natalizumab, 1 mg |
J2350 | Injection, ocrelizumab, 1 mg |
J2357 | Injection, omalizumab, 5 mg |
J2507 | Injection, pegloticase, 1 mg |
J2786 | Injection, reslizumab, 1 mg |
J3111 | Injection, romosozumab aqqg, 1 mg |
J3241 | Injection, teprotumumab trbw, 10 mg |
J3380 | Injection, vedolizumab, intravenous 1 mg |
J3399 | Injection, onasemnogene abeparvovec xioi, per treatment, up to 5x10 15 vector genomes |
J3490 | Unclassified drugs |
J3590 | Unclassified biologics |
J7340 | Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml |
J9210 | Injection, emapalumab lzsg, 1 mg |
J9999 | Not otherwise classified, antineoplastic drugs |
Q5103 | Injection, infliximab dyyb, biosimilar, (inflectra), 10 mg |
Q5104 | Injection, infliximab abda, biosimilar, (renflexis), 10 mg |
Q5109 | Injection, infliximab qbtx, biosimilar, (ixifi), 10 mg |
Q5121 | Injection, infliximab axxq, biosimilar, (avsola), 10 mg |
|
References:
|
American Academy of Allergy Asthma and Immunology.(2011) Guidelines for the site of care for administration of IGIV therapy. December 2011. Available at:http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20Resources/Guidelines-for-thesite-of-care-for-administration-of-IGIV-therapy.pdf.
Basch E, Hesketh PJ, Kris MG, et al.(2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Onc. 2011; 29(31):4189-4198.
Chataway J, Porter B, Riazi A, et al.(2006) Home versus outpatient administration of intravenous steroids for multiplesclerosis relapses: a randomized controlled trial. Lancet Neurol. 2006; 5(7):565-571.
Gutierrez-Aguirre CH, Ruiz-Arguelles G, Cantu-Rodriguez OG, et al.(2010) Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Annals of Hematology 2010; 89(10):1045-1052.
Kelly RJ, Hill A, Arnold LM, et al.(2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-92.
Mank A, van der Lelie J, de Vos R, Kersten MJ.(2011) Safe early discharge for patients undergoing high dose chemotherapy with or without stem cell transplantation: a prospective analysis of clinical variables predictive for complications after treatment. Journal of Clinical Nursing 2011; 20(3-4):388-395.
Milligan A, Hughes D, Goodwin S, et al.(2006) Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006; 15(6):330-333.
NCCN Clinical Practice Guidelines in Oncology®.(2017) © 2018 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Antiemesis (V.2.2018). Revised April 30, 2018. Prevention and Treatment of Cancer-Related Infections. (V.1.2018) Revised December 1, 2017.
Polinski JM, Kowal MK, Gagnon M, et al.(2016) Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.
Riazi A, Porter B, Chataway J, et al.(2011) A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse management Scale (MSRMS). Health Qual Life Outcomes. 2011;9:80.
|